Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 … [Read More...] about Vivani Medical initiates first-in-human GLP-1-eluting implant study
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Dexcom CEO says 2025 is ‘shaping up to be a good year’ with Stelo launch, GenAI integration
After a busy 2024, Dexcom (Nasdaq:DXCM) Chair and CEO Kevin Sayer believes the company is set for more milestones in 2025. In 2024, the company became the first to receive FDA approval for an over-the-counter (OTC) continuous glucose monitor … [Read More...] about Dexcom CEO says 2025 is ‘shaping up to be a good year’ with Stelo launch, GenAI integration
Beta Bionics to raise $114.4M in IPO
Beta Bionics today filed a prospectus outlining its aim to bring in $114.4 million in its initial public offering (IPO). Earlier this month, the maker of the iLet bionic pancreas filed a registration statement with the SEC relating to a proposed … [Read More...] about Beta Bionics to raise $114.4M in IPO
Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024. The company’s medical device business saw a 13.7% overall increase in sales, with double-digit growth both in the U.S. … [Read More...] about Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
Dexcom inks glucose biosensor partnership with Life Time
Dexcom (Nasdaq:DXCM) announced that it entered into a new partnership with Life Time Inc., an operator of athletic country clubs. Life Time Inc., a "health and wellness pioneer," has more than 170 athletic country clubs across the U.S. The chain … [Read More...] about Dexcom inks glucose biosensor partnership with Life Time
Medtronic says it has next-gen insulin pumps on the way, more to come from diabetes business
The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say. Speaking at the JP Morgan Healthcare conference this week, CEO Geoff Martha highlighted the potential opportunity in … [Read More...] about Medtronic says it has next-gen insulin pumps on the way, more to come from diabetes business
Micron Biomedical raises $33M for needle-free drug delivery tech
Micron Biomedical announced today that it added $16 million in funding to bring its Series A equity round to more than $33 million. J2 Ventures and the Global Health Investment Corporation (GHIC) led the round. Atlanta-based Micron plans to use … [Read More...] about Micron Biomedical raises $33M for needle-free drug delivery tech
Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) "unwarranted" and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce … [Read More...] about Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Aerosol drug delivery company Aerogen to expand in Ireland
Aerogen announced today that it plans to invest about $308.5 million (€300 million) to expand operations in Ireland. The company — headquartered in Dangan, Galway — expects its investment to create 725 new jobs in Ireland over the next 10 years. … [Read More...] about Aerosol drug delivery company Aerogen to expand in Ireland
BD increases U.S. syringe, IV catheter manufacturing
BD (NYSE:BDX) announced today that it plans to invest further in U.S. manufacturing to add capacity for certain critical medical devices. Those medical devices include syringes, needles and IV catheters. The Franklin Lakes, New Jersey-based … [Read More...] about BD increases U.S. syringe, IV catheter manufacturing
Insulet rolls out Omnipod 5 in more European countries
Insulet (Nasdaq:PODD) announced today that it launched the Omnipod 5 system in five more European countries. The company now offers the patch-based automated insulin delivery (AID) system in Italy, Denmark, Finland, Norway and Sweden. It comes … [Read More...] about Insulet rolls out Omnipod 5 in more European countries
In case you missed it
- Spirit Health to make new CGM available in UK
- Dexcom expects sales to grow 14% in 2025
- Senseonics to consider reverse stock split, reports strong Eversense 365 interest
- Phillips Medisize enhances inhaled drug delivery portfolio with Vectura acquisition
- Tandem inks collab with UVA to develop closed-loop automated insulin delivery tech
- CeQur raises $120M to support insulin delivery tech
- Beta Bionics is proposing an IPO
- PreEvnt to unveil non-invasive blood glucose alert device
- Abbott, Dexcom settle global CGM patent litigation
- The 5 most-read Drug Delivery Business News stories of 2024
- BD hit with FDA warning related to Pyxis medication management
- Oura raises $200M from investors including Dexcom
- Vivani Medical initiates first-in-human GLP-1-eluting implant study
- Dexcom launches generative AI platform for glucose biosensing
- BD to pay SEC $175M to settle Alaris investigation
Clinical Trials
Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This study follows FDA approval for an investigational new drug (IND) application for […]
MannKind reports positive data for inhaled insulin for children
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children. INHALE-1 looked at Afrezza in children and adolescents between 4-17 years of age. The company expects the data to support an upcoming request for a supplemental new drug application (sNDA) meeting with the FDA. It aims to […]
Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]
Abbott reports sustained benefits with Esprit drug-eluting stent
Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent. The everolimus-eluting resorbable scaffold system treats chronic limb-threatening ischemia (CLTI) below the knee (BTK). Abbott designed it to keep arteries open and deliver everolimus to support vessel healing prior to completely dissolving. The first-of-its-kind stent provides support to the vessel […]
Elixir Medical has positive data for drug-eluting bioadaptive implant
Elixir Medical announced positive data demonstrating the benefit of its DynamX coronary bioadaptor system in target lesion failure (TLF). Data highlighted the success of DynamX compared to Medtronic’s Resolute Onyx zotarolimus drug-eluting stent (DES). The study looked at complex patient populations within the INFINITY-SWEDEHEART randomized controlled trial. Data included an analysis of patients with acute […]
